Euroopa Liit - islandi - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mergæxli - Æxlishemjandi lyf - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopa Liit - islandi - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - Önnur lyf í taugakerfinu - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Euroopa Liit - islandi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost, notkunar í augu. - glaucoma, open-angle; ocular hypertension - augnlækningar - minnkun á augnþrýstingi (iop) hjá sjúklingum með gláku í augnlokum eða augnháþrýstingi sem eru ekki nægilega svör við staðbundnum beta-blokkum eða prostaglandín hliðstæðum.

Euroopa Liit - islandi - EMA (European Medicines Agency)

gilead sciences ireland uc - meðferð með eviplera rilpivirine stutt og long-term, nýrnastarfsemi alafenamide - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - meðferð fullorðnir og unglingar (aldrinum 12 ára og eldri með líkamsþyngd að minnsta kosti 35 kg) sýkt hiv veira 1 (hiv 1) án þekkt stökkbreytingar í tengslum við andstöðu við ekki núkleósíð vixlrita hemil (nnrti) flokki, nýrnastarfsemi eða meðferð með eviplera og með veiru hlaða ≤ 100,000 hiv 1 rna afrit/ml.

Euroopa Liit - islandi - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - macimorelin myndir - greiningaraðferðir, annarra - macimorelin - Þetta lyf er eingöngu ætlað til greiningar.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

Euroopa Liit - islandi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - línaklótíð - ertanlegt þarmasvepp - lyf við hægðatregðu - constella er ætlað til meðferðar við meðhöndlun á meðallagi til alvarlega einkennum í þarmi með hægðatregðu (ibs-c) hjá fullorðnum.

Euroopa Liit - islandi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - minnkun á hækkun á augnþrýstingi við langvarandi augnhvolfgláku og háþrýsting í hálsi (sem einlyfjameðferð eða sem viðbótarmeðferð við beta-blokkum).

Euroopa Liit - islandi - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, rítónavír - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - viekirax er ætlað í samsettri meðferð með öðrum lyfjum til meðferðar við langvarandi lifrarbólgu c (chc) hjá fullorðnum. fyrir lifrarbólgu c veira (hcv) arfgerð ákveðna virkni.

Euroopa Liit - islandi - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Euroopa Liit - islandi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - liðagigt, liðagigt - Ónæmisbælandi lyf - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.